Gilead ends promising PhIII leukemia study early; Arrowhead touts hep B data;

@FierceBiotech: RIP: Failure-prone KaloBios pulls the plug, calls in the liquidators. More | Follow @FierceBiotech

@JohnCFierce: Did Sanofi ($SNY) drag its feet on Lemtrada to save on the CVR? (Or is it just a lousy drug?). More from the NYT | Follow @JohnCFierce

@DamianFierce: Bloomberg's use of up-style headlines has resulted in a piece of art. Item | Follow @DamianFierce

> Gilead ($GILD) announced today that it is ending its Phase III chronic lymphocytic leukemia study for a Zydelig combo after the treatments based on its superiority to bendamustine/rituximab. Release

> Pasadena, CA-based Arrowhead Research ($ARWR) presented Phase IIa data for ARC-520 demonstrating a reduction in hepatitis B viral antigens. Release

Medical Device News

@FierceMedDev: ICYMI: Crime syndicates are hacking devices to steal private medical information for profit. Article | Follow @FierceMedDev

@VarunSaxena2: @HillaryClinton says Medicare should negotiate for lower drug prices. @BernieSanders rips Big Pharma, too. Uh oh! | Follow @VarunSaxena2

@EmilyWFierce: Gilead scores additional indications for Harvoni in hep C, HIV patients. FiercePharma story | Follow @EmilyWFierce

> J&J to launch suite of orthopedics 'solutions' for outpatient joint replacement. Report

> SurgiQuest snapped up for $265M ahead of proposed IPO, rounding out Conmed surgical offerings. Article

> Omada Health trumpets promising results from study of digital health program in Medicare patients. More

Pharma News

@FiercePharma: Bioprinting winning converts in Singapore. FiercePharmaAsia item | Follow @FiercePharma

@EricPFierce: ICYMI: Roche whacking 1,200 jobs, closing plants in US, Ireland, Italy and Spain, but building one in Switzerland. Story | Follow @EricPFierce

@CarlyHFierce: Boehringer ups the ante in IPF drug race with awareness funding. More from FiercePharmaMarketing | Follow @CarlyHFierce

> History suggests a Pfizer-Allergan hookup would mean sizable cuts in manufacturing. Story

> Big three PBMs cut loose more specialty pharmacies as scrutiny grows. Report

> Dealmaking drugmakers 'blacklist' investors to fend off activists. Article

Animal Health News

> Heska beats the Street on revenue and earnings in Q3. More

> Aratana unveils branding and partnering plans at investor day. Report

> Merck reiterates dedication to animal health with Harrisvaccines acquisition. Article

> Phibro seeks growth in aquaculture as Q1 sales growth slows. Story

> ImmuCell soars on Q3 sales growth. Item

Biotech IT News

> Datatrak accused of 'shameless and amateurish scare tactics' as proxy fight turns nasty. Report

> What represents success to 23andMe's Wojcicki? Developing a cure for a major disease. More

> WuXi NextCODE lands starring role in 100,000 Genomes Project. Story

> FDA starts beta testing 'the most advanced bioinformatics platform in the world.' More

> Data-gathering implantable chips to be tested in schizophrenia trial. Article

Pharma Marketing News

> Depomed's staffed-up Nucynta salesforce starts bringing home the bacon. Report

> Merck to forge ahead with CETP-inhibiting cholesterol med. Item

> *NSYNC's Joey Fatone lends pearly whites to Colgate diabetes campaign. Story

> Snafus waiting to happen? Pharma's digital silos stymie end-to-end promo management. More

> Boehringer ups the ante in IPF drug race with awareness funding. Article

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.